On the stock market since 2011, it operates in the world of health and science. It has 615 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
An average decline of 14% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
There is $187.6M in the vault; even if every debt were paid off, $156.7M would remain.
A loss of $74.9M against $64.8M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, FLDM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FLDM is a small company that closed last year at a loss. The road back to profit runs through spending discipline.